Search Results - "Davite, C."

Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study by Schöffski, P., Besse, B., Gauler, T., de Jonge, M.J.A., Scambia, G., Santoro, A., Davite, C., Jannuzzo, M.G., Petroccione, A., Delord, J.-P.

“…According to the results of this multi-tumour, multi-institutional Simon two-stage design phase II study the aurora kinase inhibitor danusertib was found to…”
Get full text

NMS-01940153E, an MPS1 inhibitor with anti-tumor activity in relapsed or refractory unresectable Hepatocellular carcinoma by Reig, M., Damian, S., Roberti, D., Maruzzelli, S., Crivori, P., Gianellini, L., De Pietro, M.T., Personeni, N., Sanduzzi-Zamparelli, M., Duca, M., Disconzi, L., Montagnoli, A., Galvani, A., Ardini, E., Isacchi, A., Colajori, E., Davite, C., Mahnke, L., Rimassa, L.

Get full text

815P - A new docetaxel (DOC)-based triplet regimen does not improve the outcome of metastatic (M) or locally advanced (LA) gastric cancer (GC) as compared with an epirubicin (EPI) standard triplet regimen: A GISCAD trial by Labianca, R., Rosati, G., Fazio, N., Cavanna, L., Ferrari, D., Bartolomeo, M Di, Mosconi, S., Giordano, M., Silvestris, N., Artioli, F., Iaffaioli, R.V., Veltri, E.A., Amoroso, D., Ciarlo, A., Barni, S., Cascinu, S., Davite, C., Sanzo, A Di, Casolaro, A.

“…EOX (EPI + oxaliplatin-OHP + capecitabine-CAPE) is still one of the standard regimens for M or LA GC, but the role of EPI is today widely questioned and DOC…”
Get full text

A new docetaxel (DOC)-based triplet regimen does not improve the outcome of metastatic (M) or locally advanced (LA) gastric cancer (GC) as compared with an epirubicin (EPI) standard triplet regimen: A GISCAD trial by Labianca, R., Rosati, G., Fazio, N., Cavanna, L., Ferrari, D., Bartolomeo, M Di, Mosconi, S., Giordano, M., Silvestris, N., Artioli, F., Iaffaioli, R.V., Veltri, E.A., Amoroso, D., Ciarlo, A., Barni, S., Cascinu, S., Davite, C., Sanzo, A Di, Casolaro, A.

Get full text

A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy by Borthakur, Gautam, Dombret, Herve, Schafhausen, Philippe, Brummendorf, Tim Henrik, Boissel, Nicolas, Jabbour, Elias, Mariani, Mariangela, Capolongo, Laura, Carpinelli, Patrizia, Davite, Cristina, Kantarjian, Hagop, Cortes, Jorge E

“…Danusertib is a pan-aurora kinase inhibitor with potent activity against Abl kinase including the gatekeeper T315I mutant. A phase 1 dose escalation study of…”
Get full text

815PA new docetaxel (DOC)-based triplet regimen does not improve the outcome of metastatic (M) or locally advanced (LA) gastric cancer (GC) as compared with an epirubicin (EPI) standard triplet regimen: A GISCAD trial by Labianca, R, Rosati, G, Fazio, N, Cavanna, L, Ferrari, D, Bartolomeo, M Di, Mosconi, S, Giordano, M, Silvestris, N, Artioli, F, Iaffaioli, R V, Veltri, E A, Amoroso, D, Ciarlo, A, Barni, S, Cascinu, S, Davite, C, Sanzo, A Di, Casolaro, A

“…Abstract Background EOX (EPI + oxaliplatin-OHP + capecitabine-CAPE) is still one of the standard regimens for M or LA GC, but the role of EPI is today widely…”
Get full text

Treatment of chronic hepatitis C with recombinant human interferon-alpha 2a: results of a randomized controlled clinical trial by Diodati, G, Bonetti, P, Noventa, F, Casarin, C, Rugge, M, Scaccabarozzi, S, Tagger, A, Pollice, L, Tremolada, F, Davite, C

“…Sixty consecutive patients with chronic hepatitis C were included in a randomized controlled trial of recombinant human interferon-alpha 2a vs. no treatment…”
Get more information